3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
2
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Breast Neoplasms
8
Triple Negative Breast Neoplasms
6
Head and Neck Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Melanoma
5
Urinary Bladder Neoplasms
4
Ovarian Neoplasms
4
Neoplasms
4
Stomach Neoplasms
3
Pancreatic Neoplasms
3
Neoplasm Metastasis
3
Colorectal Neoplasms
3
Carcinoma, Merkel Cell
3
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Prostatic Neoplasms
2
Gastrointestinal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Renal Cell
2
Uveal Melanoma
1
Uterine Neoplasms
1
Thyroid Neoplasms
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Sarcoma
1
Recurrence
1
Pathologic Complete Response
1
Mesothelioma, Malignant
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Interventions
Nivolumab
2
Cyclophosphamide
2
tislelizumab
1
spartalizumab
1
pembrolizumab
1
montanide ISA 51
1
glembatumumab vedotin
1
fludarabine phosphate
1
entinostat
1
cemiplimab
1
Toll-Like Receptor 1
1
Surveys and Questionnaires
1
Specimen Handling
1
Rose Bengal
1
Magnetic Resonance Spectroscopy
1
Ipilimumab
1
Interleukin-2
1
Interleukin-13
1
Focus Groups
1
Fluorodeoxyglucose F18
1
Cryosurgery
1
CTLA-4 Antigen
1
CR011-vcMMAE
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uveal Melanoma
×
cemiplimab
×
Breast
×
Clear all
NCT06022029
2025-12-24
ON-5001
OncoNano Medicine, Inc.
Phase 1
Recruiting
168 enrolled